Home Opioid Use Disorder Guideline (2023)

Clinical Guidance (Appendices)

Sort By

Newest
Most likes
Most views

Appendix 1: Methods

A1.1 Funding Guideline development activities were entirely supported by funding provided by the BC Ministry of Mental Health and Addictions...

January 14th, 2025 99 views 0 likes
Appendix 2: DSM-5-TR Criteria for Opioid Use Disorder

A. A problematic pattern of opioid use leading to clinically significant impairment or distress, as manifested by at least two...

January 14th, 2025 60 views 0 likes
Appendix 3: Titration and Dosing (A3.1 General Guidance)

A3.1 General Guidance All prescribers wishing to provide the full scope of OAT to patients in BC are required...

January 14th, 2025 50 views 0 likes
Appendix 3: Titration and Dosing (A3.2 Buprenorphine-specific Guidance)

A3.2 Buprenorphine-specific Guidance A3.2.i Buprenorphine/naloxone-specific Contraindications Allergy to buprenorphine, naloxone, or any other components of the drug product A3.2.ii...

January 31st, 2025 48 views 0 likes
Appendix 3: Titration and Dosing (A3.3 Methadone-specific Guidance)

A3.3 Methadone-specific Guidance A3.3.i Assessment Methadone-specific contraindications Hypersensitivity to methadone hydrochloride Currently taking monoamine oxidase inhibitors (MAOIs) or use within...

January 31st, 2025 54 views 0 likes
Appendix 3: Titration and Dosing (A3.4 Slow-release Oral Morphine-specific Guidance)

A3.4 Slow-release Oral Morphine-specific Guidance Slow-release oral morphine (SROM; brand name Kadian) is a long-acting, 24-hour formulation of oral morphine...

January 31st, 2025 43 views 0 likes
Appendix 3: Titration and Dosing (A3.5 Transitioning Between OAT Medications

A3.5 Transitioning Between OAT Medications Transitioning between OAT medications may be appropriate for a number of reasons including: No change...

January 31st, 2025 47 views 0 likes
Appendix 4: Emergency Department Buprenorphine/Naloxone Induction

Individuals with OUD have high rates of emergency department (ED) utilization.155-157 These high rates of utilization suggest that ED visits...

January 14th, 2025 56 views 0 likes
Appendix 5: Urine Drug Testing

Urine drug testing (UDT) at indicated intervals is the standard of care in OAT programs and can be used to...

January 14th, 2025 37 views 0 likes
Appendix 6: Take-Home Dosing

Take-home dosing (carries) of OAT may increase motivation to participate in opioid agonist treatment, improve treatment retention, facilitate virtual care,...

January 14th, 2025 45 views 0 likes
Appendix 7: Continuing Care

As with any chronic condition, individuals with opioid use disorder should receive comprehensive and continuing care. This should include ongoing...

January 14th, 2025 35 views 0 likes
Appendix 8: Clinical Opiate Withdrawal Scale (COWS)

For each item, circle the number that best describes the patient’s signs of symptoms. Rate based the apparent relationship to...

January 14th, 2025 48 views 0 likes
Appendix 9: Subjective Opiate Withdrawal Scale (SOWS)

The SOWS612 is a self-administered scale for grading opioid withdrawal symptoms. It contains 16 symptoms, the intensity of which the...

January 14th, 2025 43 views 0 likes
Appendix 10: Functional Outcome Rating Scales

Assessment of functional outcomes is increasingly recognized as an important component in patient care. Unlike screening, assessment of functional outcomes...

January 14th, 2025 39 views 0 likes